Singapore (October 22, 2014) – Vela Diagnostics announced today the availability of the Sentosa® SQ Non-Small Cell Lung Cancer (NSCLC) Panel and the Sentosa® Colorectal Cancer (CRC) Panel for Next-Generation Sequencing (NGS)-based detection of sequence variants for early access customers1 for research use only. These panels are next in the series of NGS oncology panels to be launched by Vela Diagnostics, which recently launched the CE-IVD Sentosa® SQ Melanoma Panel2.
Both the Sentosa® SQ NSCLC Panel and the Sentosa® SQ CRC Panel target 11 highly relevant genes with 28 amplicons. The Sentosa® SQ NSCLC Panel allows laboratories to check for 113 mutations while the Sentosa® SQ CRC Panel permits simultaneous screening of 112 mutations. With a turn-around time of only two days, the Vela Diagnostics NGS tests offer a very high throughput in comparison with conventional tests.
The automated Sentosa® NGS workflow supports DNA extraction, library preparation, sequencing and comprehensive result reporting. The automated reporting allows rapid and accurate sequence variant detection in both panels that helps to reduce time and costs. The easy-to-interpret report format includes automated bioinformatics and results interpretation. The Sentosa® NGS workflow also allows for seamless sample tracking and IT connectivity to ease information transfer and sample traceability.
Vela Diagnostics is the only provider to offer an automated workflow that supports both NGS and PCR tests. Currently 27 IVD PCR tests are available2. For NGS, Vela Diagnostics has recently extended its portfolio with the launch of the Sentosa® SQ HCV Genotyping Assay for early access use, the first assay of its NGS virology portfolio. Four additional NGS panels are slated for launch in the next few months. Both NGS and PCR workflows utilize the Sentosa® SX101, a liquid handling platform that performs DNA extraction, PCR set-up and library preparation. The capability to share the components between PCR and NGS workflow increases the flexibility and efficiency of the workflow. The goal of a combined workflow and complementary tests is to provide the appropriate technologies for today’s growing complex laboratory needs with improved efficiency.
About Vela Diagnostics
Vela Diagnostics is a worldwide provider of integrated molecular diagnostics workflows that address individual testing needs. Established in 2011 with its global headquarters in Singapore, Vela Diagnostics provides innovative test and data reporting solutions for Real-Time PCR and Next-Generation Sequencing. The unique ability to leverage both PCR and NGS solutions to test for infectious diseases and oncologic targets answers current diagnostic questions and enables laboratories to meet tomorrow’s complex diagnostic challenges, with regulatory status of products based on regional availability. Reliable and multi-purpose instruments help reduce the cost for optimal efficiency across laboratories of all sizes. With scalability and openchannel capabilities, laboratories also benefit from the flexibility and versatility of the systems available. For more information, please visit www.veladx.com.
Media Contact
Esther Chew
Marketing Communications Manager
esther.chew@veladx.com
+65 6690 6016
1"Products are currently not commercially available.”
2 Availability status subject to country regulatory approvals. Refer to the website for more details.
Help employers find you! Check out all the jobs and post your resume.
